CareDx CEO trades 118,000 shares under 10b5-1 plan

CareDx, Inc. director and President & CEO Hanna John Walter JR reported option exercises and share sales dated July 16, 2026.

Rhea-AI Filing Summary

CareDx, Inc. director and President & CEO Hanna John Walter JR reported option exercises and share sales dated July 16, 2026. He exercised 118,000 employee stock options at $8.2000 per share, acquiring common stock, and sold 118,000 shares in sales at weighted average prices of $36.1141 and $39.0137, effected pursuant to a Rule 10b5-1 trading plan adopted December 12, 2025. Following these transactions, he reported direct ownership of 653,448 common shares and 512,706 employee stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 118,000 shares ($3.49M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Hanna John Walter JR

Role President and CEO

Sold 118,000 shs ($4.46M)

Approx. gross sale proceeds $4.46M

Approx. exercise cost $968K

Approx. pre-tax spread $3.49M

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy) F4	118,000	$0.00	$0.00
Exercise	Common Stock	118,000	$8.20	$968K
Sale	Common Stock F1, F2	50,000	$36.1141	$1.81M
Sale	Common Stock F1, F3	68,000	$39.0137	$2.65M

Holdings After Transaction: Employee Stock Option (Right to Buy) — 512,706 contracts (Direct); Common Stock — 653,448 shares (Direct)

Footnotes (4)

1. F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.56 to $36.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter.

Key Figures

Shares sold: 118,000 shares Sale price (weighted avg): $36.1141 per share Sale price (weighted avg): $39.0137 per share +5 more

8 metrics

Shares sold 118,000 shares Total common shares sold on 2026-07-16 in two transactions

Sale price (weighted avg) $36.1141 per share Weighted average price for 50,000-share sale on 2026-07-16

Sale price (weighted avg) $39.0137 per share Weighted average price for 68,000-share sale on 2026-07-16

Options exercised 118,000 shares Common shares acquired by exercising employee stock options at $8.2000 on 2026-07-16

Exercise price $8.2000 per share Exercise price of the employee stock option grant exercised on 2026-07-16

Common shares owned 653,448 shares Direct common stock holdings reported following the sales on 2026-07-16

Employee stock options outstanding 512,706 options Employee stock options reported after the derivative transaction on 2026-07-16

10b5-1 plan adoption date December 12, 2025 Date the CEO adopted the Rule 10b5-1 trading plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Option (Right to Buy) financial

"security title: Employee Stock Option (Right to Buy) with underlying common stock"

derivative security financial

"transaction code description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CareDx (CDNA) President and CEO report in this Form 4?

He reported exercising 118,000 employee stock options at $8.2000 per share and selling 118,000 common shares on July 16, 2026, with the sales executed at weighted average prices under a Rule 10b5-1 trading plan.

How many CareDx (CDNA) shares did the CEO sell, and at what prices?

He sold 50,000 shares at a weighted average price of $36.1141 per share in trades from $35.56 to $36.51, and 68,000 shares at a weighted average of $39.0137 in trades from $39.00 to $39.15.

Were the CareDx (CDNA) insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025, and the Form 4’s Rule 10b5-1 checkbox is affirmatively marked, indicating the reported sales were made under that plan.

How many CareDx (CDNA) shares and options does the CEO hold after these trades?

After the reported transactions, he directly owned 653,448 shares of CareDx common stock and held 512,706 employee stock options, based on the total shares following transaction figures in the non-derivative and derivative tables.

What stock options did the CareDx (CDNA) CEO exercise on July 16, 2026?

He exercised 118,000 Employee Stock Options (Right to Buy) with an exercise price of $8.2000 per share, for 118,000 underlying common shares, from a grant vesting one-quarter on April 15, 2025 and monthly thereafter until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanna John Walter JR

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		M		118,000	A	$8.2	771,448	D
Common Stock	07/16/2026		S(1)		50,000	D	$36.1141(2)	721,448	D
Common Stock	07/16/2026		S(1)		68,000	D	$39.0137(3)	653,448	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$8.2	07/16/2026		M			118,000	(4)	04/14/2034	Common Stock	118,000	$0	512,706	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.56 to $36.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter.

	/s/ John Walter Hanna, Jr.	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)